Dr. James T. Dalton will discuss his drug discovery experiences in academia and the pharmaceutical industry leading to the discovery and development of enobosarm and sabizabulin. Enobosarm, a novel selective androgen receptor modulator, was evaluated in two Phase III clinical trials for muscle wasting associated with lung cancer and is now being studied as hormonal therapy for breast cancer. Sabizabulin, a novel tubulin antagonist, is in late-stage development for the treatment of COVID-19 and prostate cancer. Dr. Dalton is an elected member of the National Academy of Medicine (NAM) and is a Fellow of the American Association for the Advancement of Science (AAAS) and American Association of Pharmaceutical Scientists (MPS).